A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients - Giorgio V. Scagliotti; Denis Moro‐Sibilot; Jens Kollmeier; Adolfo Favaretto; Eun Kyung Cho; Heidrun Grosch; Martin Kimmich; Nicolas Girard; Chun-Ming Tsai; Te‐Chun Hsia; Matteo Brighenti; Christian Schumann; et al. (2019)